Keith Tapper
Stock Analyst at BMO Capital
(0.96)
# 3,184
Out of 4,667 analysts
5
Total ratings
66.67%
Success rate
-1.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $60 → $45 | $17.20 | +161.63% | 3 | Nov 20, 2024 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $2.05 | +144.50% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $16.34 | +89.71% | 1 | Jun 27, 2024 |
Neurogene
Nov 20, 2024
Maintains: Outperform
Price Target: $60 → $45
Current: $17.20
Upside: +161.63%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $2.05
Upside: +144.50%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $16.34
Upside: +89.71%